Affinia Therapeutics

About:

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.

Website: https://www.affiniatx.com/

Top Investors: RA Capital Management, Alexandria Venture Investments, F-Prime Capital, Perceptive Advisors, New Enterprise Associates

Description:

Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle and central nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties.

Total Funding Amount:

$170M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Waltham, Massachusetts, United States

Founded Date:

2019-01-01

Contact Email:

info(AT)affiniatx.com

Founders:

Aaron Tward, Aaron Tward, Botond Roska, Luk Vandenberghe, Rob Aboud, Robert Johnson

Number of Employees:

51-100

Last Funding Date:

2021-05-03

IPO Status:

Private

Industries:

© 2025 bioDAO.ai